Karyopharm Therapeutics Announces Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid Tumor Models at the American Society of Clinical Oncology (ASCO) MeetingNatick, Mass. May 25, 2012
Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announces two poster presentations covering its Selective Inhibitors of Nuclear Export (SINE), oral small molecule CRM1 antagonists, at the ASCO Meeting on June 1 – 5, 2012 at the McCormick Place Convention Center in Chicago, Illinois.
Drs. Hiromi Inoui and Robert Weiss of University of California, Davis, will present “Evaluation of selective inhibitors of nuclear export (SINE) CRM1 inhibitors for the treatment of renal cell carcinoma (RCC)”
Permanent Abstract ID: 4634.
Session Type/Title: General Poster Session: Genitourinary Cancer
Dr. Dilara McCauley of Karyopharm will present “Preclinical evaluation of selective inhibitors of nuclear export (SINE) in basal-like breast cancer (BLBC).”
Permanent Abstract ID: 1055.
Session Type/Title: General Poster Session: Breast Cancer – Triple-Negative/Cytotoxics/Local Therapy
Karyopharm’s founder and Chief Scientific Officer Dr. Sharon Shacham commented, “We are very pleased to share these new results of our continuing collaborative and internal work on the mechanisms of action and anti- tumor activity of SINE compounds in the treatment in renal and breast cancer. We look forward to evaluating KPT-330, our clinical candidate, in patients with various cancers later this year.”
About Karyopharm Therapeutics Inc.
Karyopharm is a IND stage biopharmaceutical company leading the development of small molecule modulators of nuclear transport. The Company was founded by Drs. Sharon Shacham, Michael Kauffman, Giulio Draetta and Ronald DePinho in 2008. Karyopharm has raised approximately $34M since its inception. The Company has won several grants/awards including a Biotech Investment Award by the Multiple Myeloma Research Foundation in 2010. Karyopharm’s first program is directed towards the Selective Inhibition of Nuclear Export – its SINE program – targeting CRM1, the major nuclear export protein. By inhibiting the nuclear export of tumor suppressor proteins (TSP), Karyopharm’s drug candidates force the activation of the cell’s key TSP and anti-inflammatory pathways including p53, p21, pRB, FoxO, and IκB, the body’s inhibitor of nuclear factor NF- κB. Karyopharm anticipates entering the clinic this year with its first oral SINE compound for the treatment of various cancers in humans, and has already begun studies of SINE in canine cancers, particularly lymphoma, one of the most common dog tumors. The Company is also evaluating the use of SINEs in autoimmune, viral and dermatologic disorders. Karyopharm Therapeutics is located in Natick, Massachusetts.
THIS PRESS RELEASE CONTAINS ARCHIVAL INFORMATION WHICH SHOULD NOT BE CONSIDERED CURRENT AND MAY NO LONGER BE ACCURATE